Sorry, this is not a mid-term 10-bagger. Nothing even approaching it. Remember that the market cap of this company is now 300 million. 300 million!
There is no way that Ropren sales can begin to justify a valuation like that. FDA approval is still years away, with a full Phase III trial to launch, or possible partnering (and associated revenue dilution).
Anyway, enjoy your holiday in Honkers. What a great spot. I hope you have some Solagran bubble bath handy to soothe your bottom line. I am appropriately jealous.
- Forums
- ASX - By Stock
- SLA
- rest assured
rest assured, page-2
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)